Document Detail


Treatment options for threatened miscarriage.
MedLine Citation:
PMID:  19945236     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Threatened miscarriage, as demonstrated by vaginal bleeding with or without abdominal cramps, is a common complication of pregnancy. It occurs in about 20% of recognised pregnancies. Risk of miscarriage is increased in older women and those with a history of miscarriage. Low serum levels of progesterone or human chorionic gonadotrophin (hCG) are a risk factor for miscarriage. Other risk factors include heavy bleeding, early gestational age and an empty gestational sac of >15-17 mm diameter. Clinical history and examination, maternal serum biochemistry and ultrasound findings provide valuable information about the prognosis and are important to establish in order to determine potential treatment options. Although bed rest is the most common choice of treatment, there is little evidence of its value. Other options include luteal support with progesterone, dydrogesterone or hCG. There is some evidence from clinical studies indicating that progesterone or dydrogesterone may reduce the rate of miscarriage, although further data from double-blind, randomised-controlled trials are necessary to confirm efficacy.
Authors:
N S Qureshi
Related Documents :
21076366 - Obesity in pregnancy: implications for the mother and lifelong health of the child. a c...
21331506 - Pregnancy after bariatric surgery: implications for mother and newborn.
21493146 - Complement activation: a critical mediator of adverse fetal outcomes in placental malaria?
21177636 - Hepcidin and iron species distribution inside the first-trimester human gestational sac.
12828236 - The advice-giving role of female friends and relatives during pregnancy.
14713346 - Role of redox in fetal development and neonatal diseases.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-11-27
Journal Detail:
Title:  Maturitas     Volume:  65 Suppl 1     ISSN:  1873-4111     ISO Abbreviation:  Maturitas     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2010-02-01     Completed Date:  2010-04-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7807333     Medline TA:  Maturitas     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  S35-41     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Birmingham Women's Hospital, Edgbaston, Birmingham, UK. nsq@doctors.org.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abortion, Spontaneous / prevention & control*
Abortion, Threatened / drug therapy*
Chorionic Gonadotropin / therapeutic use
Corpus Luteum
Dydrogesterone / therapeutic use*
Female
Humans
Pregnancy
Progesterone / therapeutic use*
Progestins / therapeutic use*
Reproductive Control Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Chorionic Gonadotropin; 0/Progestins; 0/Reproductive Control Agents; 152-62-5/Dydrogesterone; 57-83-0/Progesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acceptance of HIV-infected patients in assisted reproductive technique protocols.
Next Document:  Factors related to increased daytime sleepiness during the menopausal transition as evaluated by the...